Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

98 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Adjuvant platinum versus capecitabine for residual, invasive, triple-negative breast cancer: Patient-reported outcomes in ECOG-ACRIN EA1131.
Smith KL, Zhao F, Mayer IA, Tevaarwerk AJ, Garcia SF, Arteaga CL, Symmans WF, Park BH, Burnette BL, Makower DF, Block M, Morley KA, Jani CR, Mescher C, Dewani SJ, Brown-Glaberman U, Flaum LE, Mayer EL, Sikov WM, Rodler ET, DeMichele AM, Sparano JA, Wolff AC, Miller KD, Wagner LI. Smith KL, et al. Among authors: tevaarwerk aj. Cancer. 2024 May 15;130(10):1747-1757. doi: 10.1002/cncr.35187. Epub 2024 Jan 18. Cancer. 2024. PMID: 38236702 Clinical Trial.
Survivor and Clinician Assessment of Survivorship Care Plans for Hematopoietic Stem Cell Transplantation Patients: An Engineering, Primary Care, and Oncology Collaborative for Survivorship Health.
Morken CM, Tevaarwerk AJ, Swiecichowski AK, Haine JE, Williams ZT, Norslien K, Arroyo N, Zhang X, Campbell B, Mendonca EA, Juckett MB, Sesto ME. Morken CM, et al. Among authors: tevaarwerk aj. Biol Blood Marrow Transplant. 2019 Jun;25(6):1240-1246. doi: 10.1016/j.bbmt.2019.02.003. Epub 2019 Feb 11. Biol Blood Marrow Transplant. 2019. PMID: 30763727 Free PMC article.
Phase I study of continuous MKC-1 in patients with advanced or metastatic solid malignancies using the modified Time-to-Event Continual Reassessment Method (TITE-CRM) dose escalation design.
Tevaarwerk A, Wilding G, Eickhoff J, Chappell R, Sidor C, Arnott J, Bailey H, Schelman W, Liu G. Tevaarwerk A, et al. Invest New Drugs. 2012 Jun;30(3):1039-45. doi: 10.1007/s10637-010-9629-6. Epub 2011 Jan 12. Invest New Drugs. 2012. PMID: 21225315 Free PMC article. Clinical Trial.
A multicenter phase 1 study of γ -secretase inhibitor RO4929097 in combination with capecitabine in refractory solid tumors.
LoConte NK, Razak AR, Ivy P, Tevaarwerk A, Leverence R, Kolesar J, Siu L, Lubner SJ, Mulkerin DL, Schelman WR, Deming DA, Holen KD, Carmichael L, Eickhoff J, Liu G. LoConte NK, et al. Invest New Drugs. 2015 Feb;33(1):169-76. doi: 10.1007/s10637-014-0166-6. Epub 2014 Oct 17. Invest New Drugs. 2015. PMID: 25318436 Free PMC article. Clinical Trial.
In the interest of full disclosure.
Burkard ME, Tevaarwerk AJ, Wisinski KB. Burkard ME, et al. Among authors: tevaarwerk aj. Lancet Oncol. 2010 Apr;11(4):314-5; author reply 315. doi: 10.1016/S1470-2045(10)70044-9. Lancet Oncol. 2010. PMID: 20359661 No abstract available.
98 results